Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous homoharringtonine (CGX-635) in refractory or relapsed AML
2006-004517-17Phase 2Active
- Sponsor
- Stragen
- Start
- Oct 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by Stragen. Primary endpoint: Evaluation of tolerance. Started Oct 2006; status: active.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-004517-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004517-17.